Sustained efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 2-year study

Rheumatology International

Volumn 29, Issue 3, 2009, Pages 311-315

  Ringe, Johann D ^a   Farahmand, Parvis ^a   Faber, Herbert ^a   Dorst, Alfred ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bisphosphonates; Male; Non vertebral fracture; Osteoporosis; Risedronate; Vertebral fracture

Indexed keywords

ALFACALCIDOL; CALCIUM; RISEDRONIC ACID; VITAMIN D;

ARTICLE; BACKACHE; BODY HEIGHT; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMUR NECK; HIP; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY OSTEOPOROSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

AGED; BACK PAIN; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; VITAMIN D;

EID: 57649199627     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0689-2     Document Type: Article

References (19)

1. Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, London
2. JD Ringe 2007 Treatment of osteoporosis in men J Mens Health Gend (Elsevier) 4 326 333
3. Seeman E (2004) Invest in your bones. Osteoporosis in men: the 'silent epidemic' strikes men too. International Osteoporosis Foundation, Available at http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/ osteoporosis_in_men.pdf
4. JM Kaufman O Johnell E Abadie 2000 Background for studies on the treatment of male osteoporosis: state of the art Ann Rheum Dis 59 765 772 10.1136/ard.59.10.765
5. I Pande DL Scott TW O'Neill C Pritchard AD Woolf MJ Davis 2006 Quality of life, morbidity, and mortality after low trauma hip fracture in men Ann Rheum Dis 65 87 92 10.1136/ard.2004.034611
6. O Johnell JA Kanis A Odén 2004 Mortality after osteoporotic fractures Osteoporos Int 15 38 42 10.1007/s00198-003-1490-4
7. Gajic-Veljanoski O, Sebaldt RJ, Davis AM et al. (2007) Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis. Osteoporos Int (Epub ahead of print)
8. A Feldstein PJ Elmer E Orwoll M Herson T Hillier 2003 Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures. A gap in evidence-based practice guideline implementation Arch Intern Med 163 2165 2172 10.1001/archinte.163.18.2165
9. AC Feldstein G Nichols E Orwoll 2005 The near absence of osteoporosis treatment in older men with fractures Osteoporos Int 16 953 962 10.1007/s00198-005-1950-0
10. JD Ringe H Faber A Dorst 2001 Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study J Clin Endocrinol Metab 86 5252 5255 10.1210/jc.86.11.5252
11. E Orwoll M Ettinger S Weiss 2000 Alendronate for the treatment of osteoporosis in men N Engl J Med 343 604 610 10.1056/NEJM200008313430902
12. JD Ringe H Faber P Farahmand A Dorst 2006 Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol Int 26 427 431 10.1007/s00296-005-0004-4
13. PR Ebeling 2008 Osteoporosis in men N Engl J Med 358 1474 1482 10.1056/NEJMcp0707217
14. HK Kamel 2005 Male osteoporosis: new trends in diagnosis and therapy Drugs Aging 22 741 748 10.2165/00002512-200522090-00003
15. JD Ringe E Orwoll A Daifotis A Lombardi 2002 Treatment of male osteoporosis: Recent advances with alendronate Osteoporos Int 13 195 199 10.1007/s001980200013
16. JM Kaufman E Orwoll S Goemaere 2005 Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy Osteoporos Int 16 510 516 10.1007/s00198-004-1713-3
17. S Boonen ES Orwoll D Wenderoth KJ Stoner R Eusebio PD Delmas 2006 Risedronate Is effective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status JBMR 21 Suppl 1 S110 10.1359/jbmr.06s221
18. M Fransen M Woodward R Norton E Robinson M Butler AJ Campbell 2002 Excess mortality or institutionalization after hip fracture: men are at greater risk than women J Am Geriatr Soc 50 685 690 10.1046/j.1532-5415.2002.50163.x
19. JA Kanis O Johnell 2005 Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 229 238 10.1007/s00198-004-1811-2